Polyquaternium-1
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Polyquaternium-1
Description :
Polyquaternium-1 (Polidronium chloride; PQ-1) is an antimicrobial preservative and an activator of NF-κB. Polyquaternium-1 targets bacterial cell membranes, commonly used in ophthalmic surgery. Polyquaternium-1 adsorbs to the surface of microbial membranes through its polycationic properties, destroying membrane integrity and inducing potassium ion leakage, leading to bacterial death. Polyquaternium-1 exerts antimicrobial effects at a concentration of 0.001% and has low toxicity to mammalian cells. Polyquaternium-1 can be used to prepare products such as glaucoma eye drops (Travoprost preparations containing PQ-1), artificial tears, and contact lens solutions to reduce the ocular surface toxicity of traditional preservatives such as benzalkonium chloride (HY-B2232) [1][2][3].Product Name Alternative :
Polidronium (chloride)UNSPSC :
12352211Hazard Statement :
H315, H319, H335Target :
Biochemical Assay ReagentsType :
Reference compoundRelated Pathways :
OthersApplications :
COVID-19-immunoregulationField of Research :
InfectionAssay Protocol :
https://www.medchemexpress.com/polyquaternium-1.htmlPurity :
99.0Solubility :
H2O : 50 mg/mL (ultrasonic)Smiles :
OCC[N+](CCO)(C/C=C/C[N+](C)(C/C=C/C[N+](CCO)(CCO)CCO)C)CCO.[3Cl-].[n]Molecular Formula :
(C6H12N) nC16H36N2O6.3ClPrecautions :
H315, H319, H335References & Citations :
[1]Paimela T, et al. The preservative polyquaternium-1 increases cytoxicity and NF-kappaB linked inflammation in human corneal epithelial cells. Mol Vis. 2012;18:1189-96. Epub 2012 May 6.|[2]Rolando M, et, al. Ophthalmic preservatives: focus on polyquaternium-1. Expert Opin Drug Deliv. 2011 Nov;8 (11) :1425-38.|[3]Mohamed YH, et al. Acute Corneal Toxicity of Combined Antiglaucoma Topical Eyedrops. Curr Eye Res. 2016 Oct;41 (10) :1326-1330.Shipping Conditions :
Room TemperatureStorage Conditions :
4°C (Powder, sealed storage, away from moisture)Scientific Category :
Reference compound1Clinical Information :
Phase 4CAS Number :
[75345-27-6]

